Speaker(s): 

Josiah Hanson, MD - Outside Speaker from University of Washington Medical Center, Seattle, Washington-has nothing to disclose

Moderator(s): 

Tammie Ferringer, MD & Eric Hossler, MD, Staff Member, Geisinger - have nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Differentiate enfortumab TEN like dermatitis from SJS/TEN clinically and on histology
• Recognize delayed telangiectatic eruptions from loncastuximab
• Differentiate mogamulizumab related dermatitis from treatment failure in patients with CTCL and Sézary syndrome
• Learn novel treatment approaches with hedgehog inhibitors for unresectable/innumerable basal cell carcinomas while minimizing adverse events that often lead to treatment discontinuation

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Eric Hossler, MD and Ashley Hubal, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose: Robert Cooney, MD, MSMedEd, FACEP, Daniel Davis, PhD

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session:

None